[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
张俊, 秦叔逵. HER2阳性晚期胃癌分子靶向治疗的中国专家共识(2016版) [J]. 临床肿瘤学杂志, 2016, 21(9): 831-839.
|
[3]
|
Cancer Genome Atlas Research Network (2014) Com-prehensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 513, 202-209. https://doi.org/10.1038/nature13480
|
[4]
|
Cristescu, R., Lee, J., Nebozhyn, M., et al. (2015) Molecular Analysis of Gastric Cancer Identifies Subtypes Associated with Distinct Clinical Outcomes. Nature Medicine, 21, 449-456. https://doi.org/10.1038/nm.3850
|
[5]
|
Paijens, S.T., Vledder, A., de Bruyn, M., et al. (2021) Tumor-Infiltrating Lymphocytes in the Immunotherapy Era. Cellular & Molecular Immunology, 18, 842-859. https://doi.org/10.1038/s41423-020-00565-9
|
[6]
|
Shum, B., Larkin, J. and Turajlic, S. (2022) Predictive Bi-omarkers for Response to Immune Checkpoint Inhibition. Seminars in Cancer Biology, 79, 4-17. https://doi.org/10.1016/j.semcancer.2021.03.036
|
[7]
|
McDermott, D.F. and Atkins, M.B. (2013) PD-1 as a Po-tential Target in Cancer Therapy. Cancer Medicine, 2, 662-673.
https://doi.org/10.1002/cam4.106
|
[8]
|
Kang, Y.-K., Boku, N., Satoh, T., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chem-otherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 390, 2461-2471.
|
[9]
|
Kang, Y.K., Chen, L.T., Ryu, M.H., et al. (2022) Nivolumab plus Chemo-therapyversus Placebo plus Chemotherapy in Patients with HER2-Negative, Untreated, Unresectable Advanced or Re-current Gastric or Gastroesophageal Junction Cancer (ATTRACTION-4): A Randomised, Multicentre, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 23, 234-247. https://doi.org/10.1016/S1470-2045(21)00692-6
|
[10]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for advanced Gastric, Gastro-Oesophageal Junc-tion, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
|
[11]
|
Janjigian, Y.Y., Ajani, J.A., Moehler, M., et al. (2021) LBA7 Nivolumab (NIVO) plus Chemotherapy (Chemo) or Ipilimumab (IPI) vs Chemo as First-Line (1L) Treat-ment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Study. Annals of Oncology, 32, S1329-S1330.
https://doi.org/10.1016/j.annonc.2021.08.2131
|
[12]
|
Shen, L., Bai, Y.X., Lin, X.Y., et al. (2021) First-Line (1L) Nivolumab (NIVO) plus Chemotherapy (Chemo) versus Chemo in Patients (pts) with Advanced Gastric Can-cer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese Sub-group Analysis. Cancer Research, 81, CT184.
https://doi.org/10.1158/1538-7445.AM2021-CT184
|
[13]
|
Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013.
|
[14]
|
Shitara, K., Van Cutsem, E., Bang, Y.J., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemo-therapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370
|
[15]
|
Pietrantonio, F., Randon, G., Di Bartolomeo, M., et al. (2021) Predictive Role of Microsatellite Instability for PD-1 Blockade in Patients with Ad-vanced Gastric Cancer: A Meta-Analysis of Randomized Clinical Trials. ESMO Open, 6, Article ID: 100036. https://doi.org/10.1016/j.esmoop.2020.100036
|
[16]
|
Rha, S., Lee, C.K., Kim, H.S., et al. (2021) A Mul-ti-Institutional Phase Ib/II Trial of First-Line Triplet Regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer (PANTHERA Trial): Molecular Profiling and Clinical Update. Journal of Clinical Oncology, 39, 218.
https://doi.org/10.1200/JCO.2021.39.3_suppl.218
|
[17]
|
Janjigian, Y.Y., Kawazoe, A., Yanez, P., et al. (2021) The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer. Nature, 600, 727-730. https://doi.org/10.1038/s41586-021-04161-3
|
[18]
|
Fu, J., Wang, F., Dong, L.-H., et al. (2017) Preclinical Evalua-tion of the Efficacy, Pharmacokinetics and Immunogenicity of JS-001, a Programmed Cell Death Protein-1 (PD-1) Mon-oclonal Antibody. Acta Pharmacologica Sinica, 38, 710-718. https://doi.org/10.1038/aps.2016.161
|
[19]
|
Wang, F., Wei, X.L., Wang, F.H., et al. (2019) Safety, Efficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated with Toripalimab, a PD-1 Antibody in Phase Ib/II Clinical Trial NCT02915432. Annals of Oncology, 30, 1479-1486. https://doi.org/10.1093/annonc/mdz197
|
[20]
|
Keam, S.J. (2019) Toripalimab: First Global Approval. Drugs, 79, 573-578.
https://doi.org/10.1007/s40265-019-01076-2
|
[21]
|
Jiang, H.P., Zheng, Y.L., Qian, J., et al. (2020) Safety and Ef-ficacy of Sintilimab Combined with Oxaliplatin/Capecitabine as First-Line Treatment in Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in a Phase Ib Clinical Trial. BMC Cancer, 20, Article No. 760.
https://doi.org/10.1186/s12885-020-07251-z
|
[22]
|
Xu, J.M., Jiang, H.P., Pan, Y.Y., et al. (2021) LBA53 Sintili-mab plus Chemotherapy (Chemo) versus Chemo as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ORIENT-16): First Results of a Randomized, Double-Blind, Phase III Study. An-nals of Oncology, 32, S1331.
https://doi.org/10.1016/j.annonc.2021.08.2133
|
[23]
|
Huang, J., Mo, H.N., Zhang, W.L., et al. (2018) Promising Ef-ficacy of SHR‐1210, a Novel Anti-Programmed Cell Death 1 Antibody, in Patients with Advanced Gastric and Gas-troesophageal Junction Cancer in China. Cancer, 125, 742-749. https://doi.org/10.1002/cncr.31855
|
[24]
|
Xu, J.M., Bai, Y.X., Xu, N., et al. (2020) Tislelizumab plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 26, 4542-4550. https://doi.org/10.1158/1078-0432.CCR-19-3561
|
[25]
|
Chung, H.C., Arkenau, H.T., Lee, J., et al. (2019) Avelumab (Anti-PD-L1) as First-Line Switch-Maintenance or Second-Line Therapy in Patients with Advanced Gastric or Gastroesophageal Junction Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial. Journal for Im-munotherapy of Cancer, 7, 30.
https://doi.org/10.1186/s40425-019-0508-1
|
[26]
|
Bang, Y.J., Ruiz, E.Y., Van Cutsem, E., et al. (2018) Phase III, Randomised Trial of Avelumab versus Physician’s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300. Annals of On-cology, 29, 2052-2060.
https://doi.org/10.1093/annonc/mdy264
|
[27]
|
Moehler, M., Dvorkin, M., Boku, N., et al. (2021) Phase III Trial of Avelumab Maintenance after First-Line Induction Chemotherapy versus Continuation of Chemotherapy in Patients with Gastric Cancers: Results from JAVELIN Gastric 100. Journal of Clinical Oncology, 39, 966-977. https://doi.org/10.1200/JCO.20.00892
|
[28]
|
Bang, Y.J., Golan, T., Dahan, L., et al. (2020) Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric/Gastro-Oesophageal Junction Ad-enocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia/b Study (JVDJ). European Journal of Cancer, 137, 272-284.
https://doi.org/10.1016/j.ejca.2020.06.007
|
[29]
|
Kelly, R.J., Lee, J., Bang, Y.J., et al. (2020) Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junc-tion Adenocarcinoma. Clinical Cancer Research, 26, 846-854. https://doi.org/10.1158/1078-0432.CCR-19-2443
|
[30]
|
Shen, L., Li, J., Deng, Y.H., et al. (2020) Envaolimab (KN035) in Advanced Tumors with Mismatch-Repair Deficiency. Journal of Clinical Oncology, 38, S3021. https://doi.org/10.1200/JCO.2020.38.15_suppl.3021
|